PMID- 12747760
OWN - NLM
STAT- MEDLINE
DCOM- 20030814
LR  - 20231213
IS  - 1424-9634 (Electronic)
IS  - 1424-9634 (Linking)
VI  - 2
DP  - 2002 Nov 7
TI  - Characterization of cells prepared by dendritic cell-tumor cell fusion.
PG  - 15
AB  - Dendritic cells (DCs) are professional antigen-presenting cells currently being 
      discussed as a potent tool for antitumor vaccination strategies. The approach 
      consisting of the in vitro generation of DC-tumor cell hybrids may be 
      advantageous for individualized vaccines since there is no need for the 
      determination of MHC-restricted tumor-associated antigens recognized by T cells. 
      As recent vaccination studies gave varying results, we tested the impact of the 
      fusion treatment on the cells used. Polyethylene glycol-induced fusion, as well 
      as electrofusion, proved to be suitable for generating hybrid cells although at a 
      low frequency. Of note, both methods also gave rise to DCs having phagocytosed 
      apoptotic tumor cells. The expression of surface molecules relevant for specific 
      T cell stimulation was not altered by the fusion procedure and the DCs were still 
      functionally active as demonstrated by the secretion of IL-12 and the uptake of 
      antigen. The cells were able to induce a tumor-specific T cell response in vitro 
      and therefore deserve further investigation as potent tools for immunotherapy 
      trials.
FAU - Gottfried, Eva
AU  - Gottfried E
AD  - Dept. of Hematology and Oncology, University of Regensburg, Regensburg, Germany.
FAU - Krieg, Rene
AU  - Krieg R
FAU - Eichelberg, Christian
AU  - Eichelberg C
FAU - Andreesen, Reinhard
AU  - Andreesen R
FAU - Mackensen, Andreas
AU  - Mackensen A
FAU - Krause, Stefan W
AU  - Krause SW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20021107
PL  - United States
TA  - Cancer Immun
JT  - Cancer immunity
JID - 101119871
RN  - 0 ((((4-chloromethyl)benzoyl)amino)-tetramethylrhodamine)
RN  - 0 (Antigens, CD)
RN  - 0 (B7-1 Antigen)
RN  - 0 (B7-2 Antigen)
RN  - 0 (CD86 protein, human)
RN  - 0 (Fluoresceins)
RN  - 0 (Fluorescent Dyes)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Immunoglobulins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Rhodamines)
RN  - 136832-63-8 (5-chloromethylfluorescein)
RN  - 187348-17-0 (Interleukin-12)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
SB  - IM
MH  - Antigens, CD/analysis
MH  - B7-1 Antigen/analysis
MH  - B7-2 Antigen
MH  - Cell Fusion
MH  - Cell Survival
MH  - Coculture Techniques
MH  - Dendritic Cells/cytology/*immunology/metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Flow Cytometry
MH  - Fluoresceins
MH  - Fluorescent Dyes
MH  - HLA-DR Antigens/analysis
MH  - Humans
MH  - Hybrid Cells/cytology/drug effects/*immunology
MH  - Immunoglobulins/analysis
MH  - Interleukin-12/metabolism
MH  - Leukocyte Common Antigens/analysis
MH  - Membrane Glycoproteins/analysis
MH  - Microscopy, Confocal
MH  - Microscopy, Fluorescence
MH  - Neoplasms/immunology/pathology
MH  - Phagocytosis/immunology
MH  - Polyethylene Glycols/pharmacology
MH  - Rhodamines
MH  - T-Lymphocytes/cytology/immunology
MH  - Tumor Cells, Cultured/immunology
MH  - CD83 Antigen
EDAT- 2003/05/16 05:00
MHDA- 2003/08/15 05:00
CRDT- 2003/05/16 05:00
PHST- 2002/05/23 00:00 [received]
PHST- 2002/10/15 00:00 [revised]
PHST- 2002/10/18 00:00 [accepted]
PHST- 2003/05/16 05:00 [pubmed]
PHST- 2003/08/15 05:00 [medline]
PHST- 2003/05/16 05:00 [entrez]
AID - 021015 [pii]
PST - epublish
SO  - Cancer Immun. 2002 Nov 7;2:15.